Pharmaceutical Regulation Failures and Changes: Lessons Learned From OxyContin Abuse and Diversion
Document Type
Article
Publication Date
4-1-2013
School
Criminal Justice, Forensic Science, and Security
Abstract
OxyContin, a controlled-release opioid developed and produced by Purdue Pharma, was given Food and Drug Administration (FDA) approval in December 1995. By 1999, to the apparent surprise of Purdue Pharma, the Drug Enforcement Administration (DEA), and the FDA, extensive reports of OxyContin abuse and diversion began to circulate. The drug abuse assessment liability system in the United States has often been criticized and the experience with OxyContin did nothing but buttress those criticisms. However, as seven investigational hearings conducted by the U. S. Congress would expose, several changes were made to the abuse liability assessment to correct deficiencies in the system which had aggravated OxyContin abuse and diversion-a welcome sign from what many have considered an American tragedy.
Publication Title
Journal of Drug Issues
Volume
43
Issue
2
First Page
164
Last Page
175
Recommended Citation
Griffin III, O. H.,
Spillane, J. F.
(2013). Pharmaceutical Regulation Failures and Changes: Lessons Learned From OxyContin Abuse and Diversion. Journal of Drug Issues, 43(2), 164-175.
Available at: https://aquila.usm.edu/fac_pubs/7712